/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy ( CAR-T ) in light chain (AL) Amyloidosis and other serious diseases. Our lead cell therapy candidate is CAR-T NXC-201 ( NXC-201 ), currently being evaluated in our ongoing United States Phase 1b/2 NEXICART-2 (NCT06097832) clinical trial and an ex-U.S. phase 1…
$12.50
$0.22 (-1.73%)
EOD Sep 18, 2026
Negative free cash flow of -$25M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$40M
▼ -36.2% YoY
Op. Margin
—
ROIC
-31.49%
▲ +73.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$39M
▼ -56.4% YoY
Op. Cash Flow (TTM)
-$38M
▼ -64.0% YoY
Net Debt
-$231M
Net Cash Position
Cash & Equiv.
$232M
Continue Research
SourceComputed from the 10-Q filed 7 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 8 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.